The ability of donor T cells to recognize allo-MHC-peptide complexes presented by Ccl19-Cre+ FRCs appears to further license the expansion of regulatory T cells and attenuate the severity of GVHD (Shaikh et al., 2022). Here, CCL19 is linked to graft versus host disease.